Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $89,553.72 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 1,633 shares of the stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $54.84, for a total transaction of $89,553.72. Following the transaction, the insider now owns 90,598 shares in the company, valued at approximately $4,968,394.32. This trade represents a 1.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Monday, June 16th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.23, for a total transaction of $542,300.00.
• On Tuesday, June 10th, Catriona Yale sold 2,803 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.00, for a total value of $151,362.00.
• On Thursday, May 15th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $39.30, for a total value of $393,000.00.
• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The stock was sold at an average price of $37.91, for a total value of $343,957.43.

Akero Therapeutics Price Performance

AKRO stock traded down $0.70 during mid-day trading on Friday, hitting $54.20. The company had a trading volume of 1,983,828 shares, compared to its average volume of 1,019,471. The company has a 50-day moving average price of $45.88 and a 200 day moving average price of $41.10. Akero Therapeutics, Inc. has a 12-month low of $21.02 and a 12-month high of $58.40. The company has a market capitalization of $4.32 billion, a price-to-earnings ratio of -27.79 and a beta of -0.16. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. On average, research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers grew its holdings in Akero Therapeutics by 1.3% during the 4th quarter. Rhumbline Advisers now owns 105,686 shares of the company's stock valued at $2,940,000 after purchasing an additional 1,310 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Akero Therapeutics by 5.0% during the fourth quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock valued at $584,000 after buying an additional 1,000 shares during the period. Proficio Capital Partners LLC bought a new position in shares of Akero Therapeutics during the fourth quarter valued at approximately $320,000. Charles Schwab Investment Management Inc. grew its stake in shares of Akero Therapeutics by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock valued at $15,042,000 after buying an additional 8,096 shares during the last quarter. Finally, AlphaQuest LLC raised its holdings in shares of Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after buying an additional 8,147 shares during the period.

Analyst Ratings Changes

Several brokerages have recently weighed in on AKRO. Citigroup lowered their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright lifted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Finally, Bank of America boosted their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.